Johanna Lahdenranta

Johanna Lahdenranta

Company: Bicycle Therapeutics

Job title: Director – In Vivo Pharmacology


Johanna Lahdenranta, PhD, Director, in vivo pharmacology. Johanna joined Bicycle in 2018 and has been overseeing pre-clinical in vivo pharmacology work across Bicycle programs from Bicycle toxin conjugates to tumor-targeted immune cell agonists. She has 10+ years of industry experience and has previously worked on the in vivo pharmacology from large biologics to small molecules at Merrimack Pharmaceuticals and Forma Therapeutics. She obtained her PhD from University of Helsinki and did her pre-doctoral and postdoctoral training at MD Anderson Cancer Center and Massachusetts General Hospital.      



Discussion/Q&A 10:20 am

Read more

day: Day One

Fully Synthetic Tumor-Targeted Immune Cell Agonists (TICAs) Induce Anti-Cancer Immunity Through Tumor Localized CD137 Agonism 9:30 am

We have developed tumor-targeted immune cell agonists (TICAs™) based on constrained bicyclic peptides (Bicycles®) by linking Bicycles against costimulatory receptors (e.g. CD137) to those against tumor antigens (e.g. EphA2) creating potent agonists that activate costimulatory receptors selectively in the presence of tumor cells Humanized (huPBMC) tumor xenograft models, as well as transgenic huCD137 syngeneic mouse…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.